MAZE logo

Maze Therapeutics, Inc. (MAZE) EBITDA

Annual EBITDA:

$60.88M+$155.34M(+164.45%)
December 31, 2024

Summary

  • As of today, MAZE annual EBITDA is $60.88 million, with the most recent change of +$155.34 million (+164.45%) on December 31, 2024.
  • During the last 3 years, MAZE annual EBITDA has risen by +$168.09 million (+156.79%).
  • MAZE annual EBITDA is now at all-time high.

Performance

1-Year Change

+164.45%

3-Year Change

+156.79%

5-Year Change

+156.79%

15-Year Change

+156.79%

MAZE EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

84.91%
MAZE annual EBITDA is higher than 84.91% of companies in Healthcare sector

Range

All-Time High

$60.88M
MAZE annual EBITDA is currently at an all-time high

3-Year Low

-$107.21M
MAZE annual EBITDA is currently +156.79% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
MAZE previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

Mar 5, 2026
MAZE next annual earnings announcement is scheduled for Mar 5, 2026

OtherMAZEincome statement metrics

Annual Revenue

$167.50M
MAZE annual revenue is $167.50 million

Annual Net Income

$18.38M
MAZE annual net profit is $18.38 million

Annual EBIT

$57.59M
MAZE annual earnings before interest & taxes is $57.59 million

Annual EPS

$0.08
MAZE annual earnings per share is $0.08

Quarterly EBITDA:

-$32.39M+$3.43M(+9.58%)
September 30, 2025

Summary

  • As of today, MAZE quarterly EBITDA is -$32.39 million, with the most recent change of +$3.43 million (+9.58%) on September 30, 2025.
  • Over the past year, MAZE quarterly EBITDA has dropped by -$8.95 million (-38.19%).
  • MAZE quarterly EBITDA is now -46.75% below its all-time high of -$22.07 million, reached on December 31, 2023.

Performance

3-Month Change

+9.58%

1-Year Change

-38.19%

3-Year Change

-33.73%

5-Year Change

-33.73%

MAZE Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

13.41%
MAZE quarterly EBITDA is higher than 13.41% of companies in Healthcare sector

Range

All-Time High

-$22.07M
MAZE quarterly EBITDA is currently -46.75% below its historical high of -$22.07 million

3-Year Low

-$35.83M
MAZE quarterly EBITDA is currently +9.58% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
MAZE previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 5, 2026
MAZE next earnings announcement is scheduled for Mar 5, 2026

OtherMAZEincome statement metrics

Quarterly Revenue

$0.00
MAZE quarterly revenue is $0.00

Quarterly Net Income

-$30.09M
MAZE quarterly net profit is -$30.09 million

Quarterly EBIT

$0.00
MAZE quarterly earnings before interest & taxes is $0.00

Quarterly EPS

-$0.63
MAZE quarterly earnings per share is -$0.63

TTM EBITDA:

-$131.96M-$8.95M(-7.28%)
September 30, 2025

Summary

  • As of today, MAZE TTM EBITDA is -$131.96 million, with the most recent change of -$8.95 million (-7.28%) on September 30, 2025.
  • Over the past year, MAZE TTM EBITDA has dropped by -$59.38 million (-81.81%).
  • MAZE TTM EBITDA is now -444.74% below its all-time high of -$24.22 million, reached on September 1, 2023.

Performance

3-Month Change

-7.28%

1-Year Change

-81.81%

3-Year Change

-444.74%

5-Year Change

-444.74%

MAZE TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

12.43%
MAZE TTM EBITDA is higher than 12.43% of companies in Healthcare sector

Range

All-Time High

-$24.22M
MAZE TTM EBITDA is currently -444.74% below its historical high of -$24.22 million

3-Year Low

-$131.96M
MAZE TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
MAZE previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 5, 2026
MAZE next earnings announcement is scheduled for Mar 5, 2026

OtherMAZEincome statement metrics

TTM Revenue

$0.00
MAZE TTM revenue is $0.00

TTM Net Income

-$86.49M
MAZE TTM net profit is -$86.49 million

TTM EBIT

-$101.60M
MAZE TTM earnings before interest & taxes is -$101.60 million

TTM EPS

-$2.25
MAZE TTM earnings per share is -$2.25

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$60.88M
MAZE annual EBITDA is $60.88 million

Annual Net Income

$18.38M
MAZE annual net profit is $18.38 million

Annual Interest Expense

$0.00
MAZE annual interest expense is $0.00

Annual Income Tax

$1.17M
MAZE annual income tax is $1.17 million

Annual D&A

$3.30M
MAZE annual D&A is $3.30 million

MAZE EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+164.4%-38.2%-81.8%
3Y3 Years+156.8%-33.7%-444.7%
5Y5 Years+156.8%-33.7%-444.7%

MAZE EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+156.8%-46.8%+9.6%-444.7%at low
5Y5-Yearat high+156.8%-46.8%+9.6%-444.7%at low
All-TimeAll-Timeat high+156.8%-46.8%+9.6%-444.7%at low

MAZE EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$32.39M(+9.6%)
-$131.96M(-7.3%)
Jun 2025
-
-$35.83M(-3.2%)
-$123.00M(-41.1%)
Mar 2025
-
-$34.72M(-19.6%)
-$87.18M(-9.6%)
Dec 2024
$60.88M
-$29.02M(-23.8%)
-$79.53M(-9.6%)
DateAnnualQuarterlyTTM
Sep 2024
-
-$23.44M(+13.4%)
-$72.58M(+1.1%)
Mar 2024
-
-$27.06M(-22.6%)
-$73.36M(-58.5%)
Dec 2023
-$94.46M(+11.9%)
-$22.07M(+8.9%)
-$46.30M(-91.1%)
Sep 2023
-
-$24.22M
-$24.22M
Dec 2022
-$107.21M
-
-

FAQ

  • What is Maze Therapeutics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Maze Therapeutics, Inc.?
  • What is Maze Therapeutics, Inc. annual EBITDA year-on-year change?
  • What is Maze Therapeutics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Maze Therapeutics, Inc.?
  • What is Maze Therapeutics, Inc. quarterly EBITDA year-on-year change?
  • What is Maze Therapeutics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Maze Therapeutics, Inc.?
  • What is Maze Therapeutics, Inc. TTM EBITDA year-on-year change?

What is Maze Therapeutics, Inc. annual EBITDA?

The current annual EBITDA of MAZE is $60.88M

What is the all-time high annual EBITDA for Maze Therapeutics, Inc.?

Maze Therapeutics, Inc. all-time high annual EBITDA is $60.88M

What is Maze Therapeutics, Inc. annual EBITDA year-on-year change?

Over the past year, MAZE annual EBITDA has changed by +$155.34M (+164.45%)

What is Maze Therapeutics, Inc. quarterly EBITDA?

The current quarterly EBITDA of MAZE is -$32.39M

What is the all-time high quarterly EBITDA for Maze Therapeutics, Inc.?

Maze Therapeutics, Inc. all-time high quarterly EBITDA is -$22.07M

What is Maze Therapeutics, Inc. quarterly EBITDA year-on-year change?

Over the past year, MAZE quarterly EBITDA has changed by -$8.95M (-38.19%)

What is Maze Therapeutics, Inc. TTM EBITDA?

The current TTM EBITDA of MAZE is -$131.96M

What is the all-time high TTM EBITDA for Maze Therapeutics, Inc.?

Maze Therapeutics, Inc. all-time high TTM EBITDA is -$24.22M

What is Maze Therapeutics, Inc. TTM EBITDA year-on-year change?

Over the past year, MAZE TTM EBITDA has changed by -$59.38M (-81.81%)
On this page